ArticleEuropean journal of gastroenterology & hepatology2026
Agile 3+ and Agile 4 scores are accurate to detect advanced metabolic dysfunction-associated steatotic liver disease.
Article in European journal of gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognosis of metabolic dysfunction-associated steatotic liver disease (MASLD) is related to the presence of liver fibrosis (LF). The Agile 3+ and Agile 4 scores are proposed as noninvasive methods to identify advanced LF and cirrhosis, respectively, associating vibration-controlled transient elastography (VCTE) with clinical and laboratorial data.
aimTo evaluate the performance of Agile scores in the assessment of LF in MASLD patients.
methodsThis is a cross-sectional multicentric study conducted at three gastroenterology/hepatology outpatient units from Brazil, including individuals with biopsy-proven MASLD. To calculate the Agile 3+ and Agile 4 scores for the evaluation of advanced fibrosis (F≥3) and cirrhosis (F4), respectively, the formula proposed by Sanyal et al . was applied.
resultsA total of 220 patients were included, mostly women ( n = 146; 66%) and with diabetes ( n = 136; 61.5%). The prevalence of advanced fibrosis and cirrhosis was 21.82% ( n = 48) and 9.55% ( n = 21), respectively. There was a strong correlation between Agile 3+ ( r = 0.751) and VCTE ( r = 0.729) with the LF stage evaluated by liver biopsy, while the correlation of Agile 4 was moderate ( r = 0.535). However, the Agile 3+ and Agile 4 scores have shown high sensitivity and specificity (higher than 80% in all cases) when compared to liver biopsy. Also, there was significance in the area under the ROC curve, which was inferior than 0.5 for all cases.
conclusionA good correlation was confirmed between the Agile scores and VCTE with the stages of fibrosis in MASLD individuals, classifying correctly the presence of LF and cirrhosis better than VCTE solo, with a smaller indeterminate zone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.